Investors are swarming AbbVie with bullish bets, as call options surged past expectations and sent volatility ticking up.

RTX carries a strong balance sheet with a BBB+ credit rating from S&P. This is supported by $5.2 billion in cash on hand, and ...

North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With ...

AbbVie’s stock has tumbled nearly 13% over three months, rattled by global tariffs and the looming shadow of Humira’s patent ...

Berkshire Hathaway, AbbVie and Intuitive Surgical beat estimates as analysts highlight growth drivers, headwinds and ...

ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.

AbbVie posted strong Q1 2025 results and raised guidance, but early-stage obesity pipeline and fair valuation limit upside.

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

Biopharma Industry Landscape Report—uncover key trends in obesity, oncology, immunology, and AI, plus top stock picks and ...